Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical ...

Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ promising developments with their lead antibody, ORKA-001. The extended half-life of ORKA-001, ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka ...

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...

Kronos Bio (KRON – Research Report) received a Hold rating and price target from TD Cowen analyst Tyler Van Buren yesterday. The ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

On Thursday, Stifel, a financial services company, announced the initiation of coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating and a price target set at $49.00. The firm's positive ...

With our newsletters and social media channels.